A case-control study of frequency of occurrence of cardiovascular risk factors in patients with psoriasis
Keywords:Metabolic syndrome, psoriasis, obesity
AbstractObjectives Psoriasis is a chronic, inflammatory skin disease. Nowadays, its association with metabolic and vascular disorders is increasingly recognized. The study was conducted to know the association of psoriasis with metabolic syndrome (MS). Methods A hospital-based case-control study was conducted. Fifty psoriatic patients and 48 controls were recruited. Data collected included disease duration, history of smoking/alcoholism, type and severity of psoriasis, body mass index (BMI), waist circumference, blood pressure and body surface area (BSA) involvement,. Fasting blood glucose and lipid profile were measured in all patients. MS was diagnosed in presence of ≥3 criteria of the ATP III criteria. Results Patients had mild to severe psoriasis (PASI score 8.3-47). BSA affected ranged from 10% to 90%. The prevalence of MS was higher in psoriatic patients as compared to controls, but without statistical significance (12% vs. 6%, OR: 2.21, p: 0.48). MS components analyzed separately, showed a significantly higher prevalence of overweight/obesity (26% vs. 14.58% in controls), raised triglyceride levels (28% vs. 22.9%), arterial hypertension (24% vs. 12.5%), hyperglycemia (26% vs. 10.4%), hypercholesterolemia (8% vs. 2%), raised LDL levels (24% vs. 16.6%) and hypo HDL cholesterolemia (82% vs. 60.4%) in psoriatic patients than the controls. History of smoking (OR=4.91) and alcoholism (OR=2.75) was significantly higher in psoriasis patients. Conclusion Our findings demonstrate a possible association between psoriasis and MS which can favor cardiovascular events. Dermatologists treating psoriasis patients should be aware of the development of these cardiovascular risk factors and advise patients to decrease additional risk factors such as smoking or obesity.
van de Kerkhof PCM, Schalkwijk J: Psoriasis; in Bolognia JL, Jorizzo JL, Rapini RP (eds): Dermatology, ed 2. Philadelphia, Mosby Elsevier, 2008, p: 115–135.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298:321-328.
Pearson KC, Armstrong AW. Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications. Psoriasis: Targets and Therapy 2012; 2:1–11.
Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. J Invest Dermatol 2012; 132: 556–562.
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br Jr Dermatol 2007; 157: p: 68–73.
Cohen AD, Gilutz H, Henkin Y, Zaheg D, Shapiro J, Bonneh DY et al. Psoriasis and the Metabolic Syndrome. Acta DermVenereol 2007; 87: 506-509.
Mebazaa A, Asmi ME, Zidi W, Zayani Y, Rouhou RC, Ounifi SE. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol 2011; 25: 705-709.
Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-621.
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and Dyslipidaemia: A Population-based Study. Acta Derm Venereol 2008; 88:561-565.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-35.
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatol 2008; 216:152-5.
Bhat RM, Pinto HP. Lipid profile in psoriasis patients. In, Psoriasis: Targets and Therapy 2012:2 77–80.
Farshichian M, Zamanian A, Farshichian M, Monsef AR, Mahjub A, Serum lipid levels in Iranian patients with psoriasis. J Eur Assoc Deramatol Venereol 2007; 21:802-805.
Krueger JG. The immunologic basis for the treatment of psoriasis with the new biologic agents. J Am Acad Dermatol 2002; 46: 1- 23.
Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol2 007; 157: 649–655.